STOCK TITAN

Valion Bio investor 3i reports 9.9% stake

3i-affiliated holders report 9.9% beneficial ownership of Valion Bio after a 1-for-25 reverse split, while Tumim Stone Capital reports no remaining stake.

(Moderate)
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Valion Bio, Inc. (VBIO) received Amendment No. 7 to a Schedule 13D from 3i, LP, 3i Management LLC and Maier J. Tarlow, updating their ownership after recent transactions and a reverse stock split. The reporting group now has beneficial ownership of 132,671 shares of Common Stock, representing 9.9% of the outstanding common stock, based on 1,285,626 shares outstanding as of August 24, 2026.

The 132,671 shares include 90,252 shares of common stock held by 3i, LP and 42,419 shares issuable upon a combination of warrant exercises and conversions of a senior secured convertible note and Series B and Series C Convertible Preferred Stock, all subject to a 9.99% beneficial ownership limitation. Tumim Stone Capital, LLC now reports 0 shares beneficially owned. All share figures reflect Valion Bio’s 1-for-25 reverse stock split effective August 31, 2026.

Positive

  • None.

Negative

  • None.
Beneficial ownership shares 132,671 shares Shares of Valion Bio common stock beneficially owned by the 3i reporting group
Beneficial ownership percentage 9.9% Portion of Valion Bio common stock represented by 132,671 shares
Shares outstanding 1,285,626 shares Valion Bio common stock outstanding as of August 24, 2026, used for ownership calculations
Direct common shares held by 3i, LP 90,252 shares Common stock of Valion Bio directly held by 3i, LP
Shares issuable from derivatives and preferred 42,419 shares Shares of Valion Bio common stock issuable upon warrant exercises and conversions of note and preferred stock
Senior secured convertible note principal $16,253,147.10 Original principal amount of the convertible note held by 3i, LP
Reverse stock split ratio 1-for-25 Valion Bio reverse stock split effective August 31, 2026
Tumim Stone Capital ownership 0 shares (0.00%) Aggregate amount beneficially owned and percent of class reported by Tumim Stone Capital, LLC
beneficial ownership financial
"Beneficial ownership consists of 90,252 shares of Common Stock..."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Series B Convertible Preferred Stock financial
"conversions of shares of Series B Convertible Preferred Stock..."
Series B convertible preferred stock is a class of shares sold during a later-stage private financing that combines features of a loan and common stock: it usually pays priority dividends or has a priority claim if the company is sold, and it can be converted into common shares under predefined rules. Investors care because these shares affect ownership stakes and payout order—like having a reserved place in line and a ticket that can turn into regular ownership—so they influence potential returns and dilution for other shareholders.
Series C Convertible Preferred Stock financial
"conversions of shares of Series C Convertible Preferred Stock..."
Series C convertible preferred stock is a class of investment shares issued in a later private financing round that combine safety and upside: they usually pay ahead of ordinary shares if a company pays dividends or is sold, but can be converted into common stock to share in future growth. For investors this acts like a VIP ticket with a safety net—offering priority protection while preserving the option to participate in a successful exit.
beneficial ownership limitation financial
"which exercises are subject to a 9.99% beneficial ownership limitation provision..."
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
senior secured convertible note financial
"conversions of a senior secured convertible note in the original principal amount..."
A senior secured convertible note is a loan a company takes that is backed by specific assets and has first claim on repayment ahead of other creditors, but can also be exchanged for company shares under agreed conditions. For investors it signals higher priority if the company struggles (like a mortgage holder vs a general creditor) while also creating potential stock dilution if the loan is converted into equity, affecting value and recovery prospects.
reverse stock split financial
"Issuer's 1-for-25 reverse stock split effected at 12:01 a.m. Eastern Time..."
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

FAQ

What stake in Valion Bio (VBIO) do the 3i reporting persons disclose in Amendment No. 7?

They report beneficial ownership of 132,671 shares of Common Stock, representing 9.9% of Valion Bio’s common stock, based on 1,285,626 shares outstanding as of August 24, 2026, as verified with the issuer.

What does Tumim Stone Capital, LLC report as its ownership in Valion Bio (VBIO)?

Tumim Stone Capital, LLC reports 0 shares beneficially owned and therefore a 0.00% ownership percentage of Valion Bio’s common stock in this Amendment No. 7 filing.

What reverse stock split did Valion Bio (VBIO) implement and when did it become effective?

Valion Bio implemented a 1-for-25 reverse stock split of its common stock, which became effective at 12:01 a.m. Eastern Time on August 31, 2026. All share and per-share amounts in the amendment give effect to this reverse split.

What is the size of the senior secured convertible note referenced in the VBIO Schedule 13D/A?

The reporting persons reference a senior secured convertible note with an original principal amount of $16,253,147.10, held by 3i, LP. Shares issuable upon conversion of this note are subject to a 9.99% beneficial ownership limitation Blocker.

Which securities besides common stock can convert into Valion Bio (VBIO) shares for the 3i reporting group?

Shares may be issued upon exercises of common stock purchase warrants and conversions of Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, and the senior secured convertible note, with each such conversion or exercise limited by a 9.99% Beneficial Ownership Limitation Blocker.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





918942202

(CUSIP Number)
Maier J. Tarlow
2 Wooster Street, 2nd Floor,
NEW YORK, NY, 10013
(646) 845-0040

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
09/03/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D




Comment for Type of Reporting Person:
As more fully described in Item 5 of this Amendment No. 7 (as defined in Item 1 below), such shares and percentage are based on 1,285,626 shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") outstanding as of August 24, 2026, as verified with the Issuer. Beneficial ownership consists of 90,252 shares of Common Stock directly held by 3i, LP and 42,419 shares of Common Stock issuable in any combination upon (i) exercises of certain common stock purchase warrants (the "Warrants") held directly by 3i, LP, which exercises are subject to a 9.99% beneficial ownership limitation provision (a "Blocker"), (ii) conversions of a senior secured convertible note in the original principal amount of $16,253,147.10 (the "Note") held directly by 3i, LP, which conversions are subject to a Blocker, (iii) conversions of shares of Series B Convertible Preferred Stock, par value $0.0001 per share, of the Issuer (the "Series B Preferred Stock") directly held by 3i, LP, which conversions are subject to a Blocker, and (iv) conversions of shares of Series C Convertible Preferred Stock, par value $0.0001 per share, of the Issuer (the "Series C Preferred Stock") directly held by the 3i, LP, which conversions are subject to a Blocker. Unless the context expressly dictates otherwise, all references to share and per share amounts in this Amendment No. 7 give effect to the Issuer's 1-for-25 reverse stock split effected at 12:01 a.m. Eastern Time on August 31, 2026.


SCHEDULE 13D






SCHEDULE 13D




Comment for Type of Reporting Person:
As more fully described in Item 5 of this Amendment No. 7, such shares and percentage are based on 1,285,626 shares of Common Stock outstanding as of August 24, 2026, as verified with the Issuer. Beneficial ownership consists of 90,252 shares of Common Stock indirectly held by the reporting person and 42,419 shares of Common Stock issuable in any combination upon (i) exercises of the Warrants indirectly held by the reporting person, which exercises are in each case subject to a Blocker, and (ii) conversions of the Note, shares of Series B Preferred Stock and shares of Series C Preferred Stock indirectly held by the reporting person, which conversions are in each case subject to a Blocker.


SCHEDULE 13D




Comment for Type of Reporting Person:
As more fully described in Item 5 of this Amendment No. 7, such shares and percentage are based on 1,285,626 shares of Common Stock outstanding as of August 24, 2026, as verified with the Issuer. Beneficial ownership consists of 90,252 shares of Common Stock indirectly held by the reporting person and 42,419 shares of Common Stock issuable in any combination upon (i) exercises of the Warrants indirectly held by the reporting person, which exercises are in each case subject to a Blocker, and (ii) conversions of the Note, shares of Series B Preferred Stock and shares of Series C Preferred Stock indirectly held by the reporting person, which conversions are in each case subject to a Blocker.


SCHEDULE 13D


3i, LP
Signature:/s/ Maier J. Tarlow
Name/Title:Maier J. Tarlow, manager of 3i Management LLC, general partner of 3i, LP
Date:09/03/2026
Tumim Stone Capital, LLC
Signature:/s/ Maier J. Tarlow
Name/Title:Maier J. Tarlow, manager of 3i Management LLC, manager of Tumim Stone Capital, LLC
Date:09/03/2026
3i Management LLC
Signature:/s/ Maier J. Tarlow
Name/Title:Maier J. Tarlow, Manager
Date:09/03/2026
Maier J. Tarlow
Signature:/s/ Maier J. Tarlow
Name/Title:Maier J. Tarlow
Date:09/03/2026